Tenax Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Tenax Therapeutics, Inc.
Finance Watch: Rivus Raises $132m In Series B Cash To Fund Obesity Drug Trials
VC funding slowed recently, but public company financings kept up a brisk pace with follow-on public offerings for Allakos and Alpine, private placements for Ventyx and Syros, and Albireo’s royalty deal. In restructuring updates, Biogen raised $592m in a real estate deal and Acerus is assessing options.
ITF Pharma Plans October US Roll-Out Of Liquid Riluzole Formulation For ALS
Early engagement with US payers suggests openness to covering a liquid form of riluzole, because the tablet version is proven, but it's impossible to take for many ALS patients, says Italfarmaco subsidiary ITF Pharma.
Finance Watch: Second Quarter Begins With Solid Base For Biopharma VC, Shaky Ground For Acorda
First quarter VC investments in biopharma set high expectations for the second quarter; Acorda cuts jobs after patent litigation defeat, plus other strategic realignments; no new US IPOs, but Europe has three; and notable follow-on offerings.
Pipeline Watch: Evolocumab, Roxadustat And SB-204, Top-line Results
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
- Medical Devices
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Oxygen Biotherapeutics, Inc.
- Synthetic Blood International, Inc.
- PrecisionMed, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.